A detailed history of Goldman Sachs Group Inc transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 113,972 shares of AURA stock, worth $934,570. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,972
Previous 1,029,921 88.93%
Holding current value
$934,570
Previous $7.79 Million 86.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.9 - $10.36 $6.32 Million - $9.49 Million
-915,949 Reduced 88.93%
113,972 $1.02 Million
Q2 2024

Aug 13, 2024

BUY
$6.81 - $7.89 $226,623 - $262,563
33,278 Added 3.34%
1,029,921 $7.79 Million
Q1 2024

May 15, 2024

SELL
$7.09 - $9.24 $288,251 - $375,661
-40,656 Reduced 3.92%
996,643 $7.82 Million
Q4 2023

Feb 13, 2024

BUY
$7.02 - $11.98 $309,560 - $528,282
44,097 Added 4.44%
1,037,299 $9.19 Million
Q3 2023

May 14, 2024

SELL
$8.97 - $12.38 $395,550 - $545,920
-44,097 Reduced 4.25%
993,202 $8.91 Million
Q3 2023

Nov 14, 2023

SELL
$8.97 - $12.38 $302,306 - $417,230
-33,702 Reduced 3.28%
993,202 $8.91 Million
Q2 2023

May 14, 2024

BUY
$8.51 - $13.33 $6.28 Million - $9.84 Million
738,406 Added 255.95%
1,026,904 $12.7 Million
Q2 2023

Aug 14, 2023

BUY
$8.51 - $13.33 $6.28 Million - $9.84 Million
738,406 Added 255.95%
1,026,904 $12.7 Million
Q1 2023

May 14, 2024

BUY
$8.88 - $12.11 $736,311 - $1 Million
82,918 Added 40.33%
288,498 $2.68 Million
Q1 2023

May 11, 2023

BUY
$8.88 - $12.11 $736,311 - $1 Million
82,918 Added 40.33%
288,498 $2.68 Million
Q4 2022

May 14, 2024

SELL
$9.86 - $14.59 $8.2 Million - $12.1 Million
-831,719 Reduced 80.18%
205,580 $2.16 Million
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $2.03 Million - $3 Million
205,580 New
205,580 $2.16 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $240M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.